Multiple sclerosis, interferon beta and clinical thyroid dysfunction.
The objective of this study was to investigate frequency and presentation of clinical thyroid dysfunction in patients treated with interferon beta (IFN-beta). We have collected the cases of clinical thyroid dysfunction in 700 consecutive patients receiving IFN-beta for multiple sclerosis (MS). Five patients (four women, one man) treated with IFN-beta1b developed hyperthyroidism. Three of them have secondary progressive MS, and two have relapsing-remitting MS. It was necessary to stop IFN-beta in three cases; these patients still require carbimazole after several months. In the two other cases, hyperthyroidism disappeared spontaneously. Two patients (one man and one woman) treated with IFN-beta1a developed hypothyroidism. One of them required l-thyroxine. Lastly, an increased thyroid volume without modification of thyroid hormones plasma levels was discovered in a patient receiving IFN-beta1a. Among patients treated with IFN-beta, clinical thyroid dysfunction is much rarer than laboratory thyroid dysfunction. However, this side-effect is sometimes severe.
Kreisler
A
A
Department of Neurology, Lille University Hospital, France.
de Seze
J
J
Stojkovic
T
T
Delisse
B
B
Combelles
M
M
Vérier
A
A
Hautecoeur
P
P
Vermersch
P
P
D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D005260:Female; D006042:Goiter / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy; D006801:Humans; D006980:Hyperthyroidism / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy; D007037:Hypothyroidism / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000009:adverse effects*; D008297:Male; D020528:Multiple Sclerosis, Chronic Progressive / Q000150:complications* / Q000188:drug therapy; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications* / Q000188:drug therapy; D013959:Thyroid Diseases / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D013974:Thyroxine / Q000627:therapeutic use
D013956:Antithyroid Agents; D000068576:Interferon beta-1b; D016899:Interferon-beta; D013974:Thyroxine; D000068556:Interferon beta-1a